Author name: Gertrud U. Rey

Gertrud Rey (who also goes by Trudy Rey) is a trained virologist who resides in Atlanta, Georgia. She has a PhD in molecular genetics and biochemistry from Georgia State University, where her studies involved the analysis of various aspects of the genetics of West Nile virus and simian hemorrhagic fever virus. After finishing the PhD program in 2007, she accepted a post-doctoral fellowship at the Centers for Disease Control and Prevention, where she continued to study virology in the context of respiratory syncytial virus, with a more pronounced focus on immunology. During that time, she was also a lecturer at Georgia State University, where she designed an undergraduate biology course and supervised teaching assistants at the university’s biology laboratory. In 2012, she decided to retire from bench science and lecturing to pursue a career in patent law. She is now registered as a patent agent at the U.S. Patent and Trademark Office, and works for a major law firm. Her day to day responsibilities include preparing and prosecuting U.S. and international patent applications in the field of molecular and cell biology, virology, biochemistry, genetic engineering, tissue engineering, transgenic biology, stem cell research, immunology, drug delivery, phage therapeutics, and medical devices. However, Trudy still spends much of her free time communicating science, both for virology blog, and for her very own YouTube channel, where she hosts a show about viruses called “Catch This.” You can also find her on X, under the handle “Dr. T.” Trudy was also a guest on TWiV 179 and 424.

Toll to the Rescue

by Gertrud U. Rey Transmissible spongiform encephalopathies (TSEs) include a variety of fatal neurodegenerative diseases caused by infectious proteins called prions. Although prions are not viruses, their ability to self-propagate without a nucleic acid intermediate has always fascinated virologists, causing them to adopt prions into their repertoire of pathogenic agents. Common TSEs comprise scrapie in …

Toll to the Rescue Read More »

CRISPR-ing HIV-1

By Gertrud U. Rey Although antiretroviral therapy (ART) has been highly effective at controlling HIV-1 viral loads in the bloodstream of infected individuals, the virus remains latent in infected cells and starts replicating within a couple of weeks upon termination of therapy.

Scroll to Top